GRASP Table Query Reference¶
Phenotype¶
The following phenotypes are stored in the GRASP database (there are 1,209 of them):
| Phenotype | ID |
|---|---|
| 5-HTT serotonin transporter levels, in brain | 999 |
| 93 circulating phenotypes | 557 |
| ADD | 1021 |
| ADHD | 566 |
| ADHD and conduct disorder symptoms | 663 |
| ADHD in adults | 662 |
| ADHD, inattention and hyperactivity-impulsivity tests | 496 |
| ADHD, methylphenidate treatment response in | 660 |
| Abdominal aortic aneurysm | 714 |
| Abdominal subcutaneous and visceral adipose depots | 160 |
| Acetaminophen toxicity in blood cell lines | 965 |
| Activated partial thromboplastin time (aPTT) and activated protein C resistance | 377 |
| Activated partial thromboplastin time (aPTT) and prothrombin time | 202 |
| Activated partial thromboplastin time (aPTT), in blood | 811 |
| Acute lung injury | 983 |
| Acute lung injury following major trauma | 32 |
| Acute respiratory distress syndrome | 463 |
| Adaptation of normoxic and mild-hypoxic inhabitants | 169 |
| Addiction phenotypes (alcohol, nicotine, marijuana, cocaine, opiates, other drugs) | 989 |
| Adipocyte fatty acid-binding protein concentration, in serum | 1113 |
| Adiponectin levels in women | 905 |
| Adiponectin levels, in plasma | 679 |
| Adiponectin, high molecular weight, in serum | 1073 |
| Adiponectin, in plasma | 1167 |
| Adiponectin, in serum | 105 |
| Adiposity traits | 211 |
| Adolescent idiopathic scoliosis | 546 |
| Adolescent idiopathic scoliosis, in women | 1152 |
| Advanced age-related macular degeneration subtypes | 205 |
| Age at menarche | 528 |
| Age at menarche and age at natural menopause | 458 |
| Age at menarche, age at menopause | 1186 |
| Age at menopause | 20 |
| Age at menopause (early menopause) | 415 |
| Age at natural menopause | 709 |
| Age-related cataract (ARC) and Alzheimer disease (AD) | 300 |
| Age-related macular degeneration | 197 |
| Age-related macular degeneration (AMD), wet neovascular | 580 |
| Age-related macular degeneration, advanced | 822 |
| Age-related macular degeneration, exudative | 1122 |
| Aging successfully (longevity and low disease burden) | 221 |
| Airflow obstruction | 242 |
| Albumin and total protein, serum | 313 |
| Albumin:globin ratio, serum | 414 |
| Albuminuria, in urine | 1002 |
| Alcohol and nicotine co-dependence | 112 |
| Alcohol consumption | 166 |
| Alcohol consumption (heavy) | 454 |
| Alcohol craving | 109 |
| Alcohol dependence | 338 |
| Alcohol dependence in bipolar cases and non-bipolar controls | 1115 |
| Alcohol withdrawal symptoms | 1169 |
| Alcohol-related and sporadic pancreatitis | 356 |
| Allele-specific FAIRE regulation in lymphoblastoid cell lines | 273 |
| Allergic rhinitis and grass sensitization | 1157 |
| Alopecia (early-onset androgenetic alopecia) | 196 |
| Alopecia areata | 858 |
| Alpha-tocopherol after vitamin E supplementation in men, serum | 86 |
| Alzheimer’s disease | 83 |
| Alzheimer’s disease with psychotic symptoms | 1146 |
| Alzheimer’s disease, MRI atrophy as a QTL for | 948 |
| Alzheimer’s disease, age at onset | 1147 |
| Alzheimer’s disease, late onset | 223 |
| Amygdala activation, in youths, with and without bipolar disorder | 807 |
| Amygdala reactivity | 249 |
| Amyloid A levels, in serum | 952 |
| Amyotrophic Lateral Sclerosis (ALS) | 290 |
| Amyotrophic Lateral Sclerosis (ALS), sporadic | 100 |
| Androgen levels in men, serum | 279 |
| Androgenic alopecia (Male pattern baldness) | 664 |
| Anemia, ribavirin-induced in hepatitis C treatment | 864 |
| Angiotensin-converting enzyme (ACE) activity, in serum | 779 |
| Ankle-brachial index (ABI) | 50 |
| Ankylosing spondylitis | 778 |
| Anorexia nervosa | 940 |
| Anthropometric traits (body mass index, waist to hip ratio, height, obesity grade) | 513 |
| Anti-cyclic citrullinated peptide titer | 695 |
| Anti-cytomegalovirus antibody response | 1141 |
| Antibody response to anthrax vaccine adsorbed | 176 |
| Antibody response to smallpox vaccine | 137 |
| Antibody titer to hepatitis B vaccination | 1088 |
| Antidepressant efficacy in major depressive disorder | 339 |
| Antidepressant response in major depressive disorder | 159 |
| Antihypertensive response to an Angiotensin II Receptor Blocker | 150 |
| Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis | 234 |
| Antiphospholipid antibodies | 490 |
| Antipsychotic drug-induced weight gain, severe | 151 |
| Antipsychotic treatment outcomes | 392 |
| Antipsychotic-induced tardive dyskinesia | 1103 |
| Antisocial behavior | 814 |
| Antisocial behavior (adult) | 336 |
| Antithrombin, in plasma | 562 |
| Anxiety (childhood anxiety) | 515 |
| Anxiety spectrum disorders | 820 |
| Aortic root diameter | 975 |
| Arsenic metabolism and toxicity | 63 |
| Arterial stiffness | 765 |
| Arthritis (juvenile idiopathic arthritis) | 48 |
| Arthritis (juvenile rheumatoid arthritis) | 530 |
| Asparaginase sensitivity in blood cell lines | 936 |
| Aspartate aminotransferase (AAT) levels, in serum | 1120 |
| Asperger disorder | 966 |
| Aspirin hydrolytic activity, in plasma | 489 |
| Aspirin-exacerbated respiratory disease | 371 |
| Asthma | 1 |
| Asthma (acute bronchodilator response) | 487 |
| Asthma (adult) | 373 |
| Asthma (childhood allergic asthma) | 1004 |
| Asthma (childhood asthma) | 594 |
| Asthma (childhood asthma, age at onset) | 146 |
| Asthma (severe asthma) | 149 |
| Asthma exacerbation | 563 |
| Asthma response to bronchodilators | 228 |
| Asthma response to inhaled corticosteroids | 135 |
| Asthma, aspirin-intolerant | 937 |
| Asthma, childhood | 1069 |
| Asthma, severe exacerbations | 1076 |
| Asthma, toluene diisocynate induced | 682 |
| Astigmatism | 420 |
| Atherosclerosis and myocardial infarction | 978 |
| Atopic dermatitis | 321 |
| Atopy | 942 |
| Atopy and allergic rhinitis | 1053 |
| Atopy, with and without asthma | 757 |
| Atrial fibrillation | 139 |
| Atrial fibrillation, atrial flutter | 592 |
| Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity | 283 |
| Autism | 277 |
| Autism like traits | 759 |
| Autism spectrum disorders | 74 |
| Autism spectrum disorders with language delay | 1034 |
| Autism, gender differences | 961 |
| Autism, monoallelic expression in blood cell lines | 1063 |
| Autoimmune thyroid disease (Grave’s disease and Hashimoto’s thyroiditis) | 274 |
| Azoospermia and oligozoospermia | 711 |
| B-vitamin level (Vitamin B6, Vitamin B12) concentrations, folate and homocysteine, in serum | 697 |
| Barrett’s esophagus | 292 |
| Behavior, childhood | 1091 |
| Behcet’s disease | 707 |
| Behet’s disease | 307 |
| Beta-2 microglobulin, in plasma | 451 |
| Beta-thalassemia/hemoglobin E disease | 801 |
| Beta-trace protein levels, in plasma | 422 |
| Bicuspid aortic valve | 784 |
| Biliary atresia | 835 |
| Bilirubin levels | 431 |
| Bilirubin levels (total bilirubin) | 539 |
| Bilirubin levels, in serum | 703 |
| Bilirubin levels, in serum, unconjugated | 1183 |
| Biomarkers (liver function, butrylycholinesterase, CRP, ferritin, glucose, HDL cholesterol, insulin, LDL cholesterol, triglycerides, uric acid), body mass index (BMI) | 1132 |
| Biomarkers (natriuretic peptides, vitamin K, vitamin D, CD40L, osteoprotegerin, P-selectin, TNFR2, TNFa, liver function, osteocalcin, CRP, IL6, sICAM, MCP1, myelperoxidase), in plasma or serum | 605 |
| Bipolar disorder | 334 |
| Bipolar disorder (mood-incongruent psychotic bipolar disorder) | 340 |
| Bipolar disorder and schizophrenia | 909 |
| Bipolar disorder and white matter integrity | 386 |
| Bipolar disorder with irritable or elated mania in severe episodes | 421 |
| Bipolar disorder with negative mood delusions | 310 |
| Bipolar disorder with seasonal pattern mania | 276 |
| Bipolar disorder, affective | 845 |
| Bipolar disorder, age of onset in | 993 |
| Bipolar disorder, personality traits within | 1006 |
| Bipolar disorder, schizoaffective | 719 |
| Birth weight | 380 |
| Birth weight, length, head circumference and fat mass | 519 |
| Bisphosphonate-related osteonecrosis of the jaw | 21 |
| Bivariate analysis of femoral neck bone mineral density and age at menarche | 525 |
| Bladder cancer | 725 |
| Bleomycin sensitivity, in blood samples | 945 |
| Blood biomarkers in chronic obstructive pulmonary disease | 358 |
| Blood cell count (lymphocyte count) and gene expression | 23 |
| Blood cell count (monocyte count) | 416 |
| Blood cell count (neutrophil count) | 799 |
| Blood cell counts and other traits (platelet count (PLT), red cell count, white cell count, hemoglobin, urate, GGT, alkaline phosphatase, AST, ALT, creatinine kinase, total protein, albumin, blood urea nitrogen, serum creatinine, HDL cholesterol, triglycerides) | 787 |
| Blood cell counts and traits, in red and white blood cells | 402 |
| Blood cell counts and traits, in red blood cells | 555 |
| Blood cell counts, in white cells | 1080 |
| Blood cell counts, in white cells in leukemia patients in remission | 1033 |
| Blood cell traits (red blood cell count, hemoglobin, hematocrit) | 1209 |
| Blood cell traits, in red blood cells | 147 |
| Blood group types in women | 165 |
| Blood phenotypes and cell counts (fibrinogen, FVII, PAI1, vWF, tPA, D-dimer, platelet aggregation, viscosity, hemoglobin, red blood cell counts) | 606 |
| Blood pressure | 930 |
| Blood pressure and arterial stiffness | 612 |
| Blood pressure and/or hypertension | 673 |
| Blood pressure lowering with thiazide-diuretic treatment | 793 |
| Blood pressure, CVD RF and other traits (body mass index (BMI), height, waist circumference, weight, leptin, percent body fat, HDL cholesterol, LDL cholesterol, total cholesterol, triglycerides, fasting glucose, thyroid stimulating hormone, C-reactive protein (CRP)) | 685 |
| Blood pressure, CVD RF and other traits (body mass index (BMI), waist:hip ratio, pulse rate, bone mineral density (BMD)) | 704 |
| Blood pressure, CVD RF and other traits (body mass index (BMI), waist:hip ratio, renin activity in plasma, aldosterone concentration in plasma, BNP levels in plasma, alcohol consumption) | 907 |
| Blood pressure, early onset hypertension | 705 |
| Body fat percentage | 1075 |
| Body mass index (BMI) | 47 |
| Body mass index (BMI) and asthma | 493 |
| Body mass index (BMI) in adolescents and young adults | 548 |
| Body mass index (BMI), height, weight, waist circumference | 918 |
| Bone geometry (femoral neck) | 800 |
| Bone geometry (femoral neck), and appendicular lean mass | 1175 |
| Bone mass and geometry | 608 |
| Bone mineral density (BMD) | 194 |
| Bone mineral density (BMD) (wrist) | 943 |
| Bone mineral density (BMD) and osteoporosis-related phenotypes | 1170 |
| Bone mineral density (BMD), cortical density, in men | 951 |
| Bone mineral density (BMD), in women | 794 |
| Bone mineral density (hip), in women | 1036 |
| Bone mineral density and fat mass | 460 |
| Bone mineral density in premenopausal women | 335 |
| Bone mineral density of forearm | 518 |
| Bone mineral density, low-trauma fracture | 123 |
| Bone mineral traits | 970 |
| Bone mineral traits, uni and bivariate analyses, in men | 1014 |
| Bone size | 658 |
| Bone size and body lean mass | 345 |
| Bone thickness, bone strength, osteoporotic fracture risk | 227 |
| Bone-related traits (pleiotropy in bone mineral density (BMD), bone geometry, muscle mass, bone quantitative ultrasound) | 1049 |
| Brachial circumference | 106 |
| Brain A_ levels | 452 |
| Brain activation patterns in response to human facial expressions | 238 |
| Brain aging, MRI and cognition phenotypes | 609 |
| Brain derived neurotrophic factor levels, in serum | 1162 |
| Brain imaging phenotypes | 785 |
| Brain infarcts, covert MRI-defined | 774 |
| Brain microstructure; intellectual performance | 208 |
| Brain neural connectivity | 265 |
| Brain size | 1192 |
| Brain structure | 798 |
| Brain white matter hyperintensity | 1064 |
| Brain white matter integrity | 81 |
| Breast and ovarian cancer risk in BRCA1 carriers | 506 |
| Breast cancer | 8 |
| Breast cancer (ER-positive) and post-menopausal estradiol concentrations, in plasma | 494 |
| Breast cancer and prostate cancer | 510 |
| Breast cancer in males | 305 |
| Breast cancer meta | 903 |
| Breast cancer risk | 855 |
| Breast cancer risk in Ashkenazi Jewish women without BRCA1/2 mutations | 427 |
| Breast cancer risk related to menopausal hormone therapy | 457 |
| Breast cancer survival | 12 |
| Breast cancer survival (early-onset breast cancer) | 418 |
| Breast cancer, BRCA1-positive | 901 |
| Breast cancer, BRCA2-positive | 931 |
| Breast cancer, ER negative | 500 |
| Breast cancer, adverse effects to aromatase inhibitors | 904 |
| Breast cancer, clinical outcomes of adjuvant tamoxifen therapy | 1199 |
| Breast cancer, early onset | 640 |
| Breast cancer, estrogen receptor-negative | 1159 |
| Breast cancer, hormonal receptor-positive | 285 |
| Breast cancer, lapatinib-induced hepatotoxicity in | 981 |
| Breast cancer, prostate cancer | 576 |
| Breast cancer, sporadic post-menopausal | 589 |
| Breast size | 215 |
| Bronchopulmonary dysplasia | 1109 |
| Butyrylcholinesterase activity, in serum | 1112 |
| C-reactive protein (CRP) | 115 |
| C-reactive protein (CRP) and white blood cell (WBC) | 224 |
| C-reactive protein (CRP) levels, in plasma, in women | 635 |
| C-reactive protein (CRP) levels, in serum | 636 |
| CD4:CD8 T cell ratios | 775 |
| CVD outcomes (CVD, MI, stroke, CHD death, atrial fibrillation, heart failure) | 614 |
| CVD risk factors and quantitative traits (blood pressure, heart rate, LDL cholesterol, HDL cholesterol, total cholesterol, triglycerides, glucose, insulin, height, weight, waist circumference) | 899 |
| Cachexia | 924 |
| Caffeine-induced insomnia | 216 |
| Calcium intake levels and metabolic syndrome | 1193 |
| Calcium levels, in serum | 871 |
| Cannabis dependence | 1060 |
| Cannabis use initiation | 237 |
| Capecitabine sensitivity | 253 |
| Carbamazepine ADRs | 960 |
| Carboplatin cytotoxicity and gene expression, in blood cell lines | 656 |
| Cardiac structure and function measurements (LV mass, internal dimensions, wall size, systolic dysfunction, aortic root size, left atrial size) | 721 |
| Cardiac structure and systolic function | 405 |
| Cardiovascular disease adverse events in renal patients treated with calcineurin inhibitors | 577 |
| Cardiovascular disease events in migraineurs | 1090 |
| Cardiovascular disease risk | 1155 |
| Carotenoid and tocopherol levels, in plasma | 681 |
| Carotid artery intimal-media thickness | 481 |
| Carotid atherosclerosis in HIV-infected men | 758 |
| Carotid intima-media thickness | 365 |
| Carotid intima-media thickness and plaque | 1124 |
| Carotid-femoral pulse wave velocity | 1168 |
| Cataracts (diabetic cataract) | 352 |
| Cataracts in T2D | 873 |
| Caudate volume | 1031 |
| Celiac disease | 591 |
| Celiac disease and Rheumatoid arthritis | 1008 |
| Cell-Free DNA, serum | 127 |
| Central cornea thickness | 837 |
| Central corneal thickness | 235 |
| Central corneal thickness and keratoconus | 411 |
| Cerebrospinal fluid tau | 512 |
| Ceruloplasmin levels, in serum | 1171 |
| Cervical cancer | 479 |
| Chemerin levels, in plasma | 810 |
| Chemotherapeutic response (cytabarine, 5’deoxyfluorouridine, carboplatin, cisplatin), in blood cell lines | 1084 |
| Chewing tobacco associated oral cancers | 119 |
| Childhood dental caries | 1131 |
| Chronic fatigue syndrome | 1127 |
| Chronic hepatitis B | 699 |
| Chronic hepatitis B progression | 1145 |
| Chronic kidney disease (CKD) | 104 |
| Chronic kidney disease (CKD) and kidney stones | 877 |
| Chronic kidney disease (CKD) and renal traits | 232 |
| Chronic obstructive pulmonary disease (COPD) | 696 |
| Chronic obstructive pulmonary disease (COPD), smoking behavior in | 1065 |
| Chronic widespread pain | 289 |
| Circulating 25-hydroxyvitamin D | 351 |
| Circulating PCSK9 Levels | 97 |
| Circulating estradiol, testosterone, and sex hormone-binding globulin in postmenopausal women | 185 |
| Circulating galectin-3 levels | 331 |
| Circulating haptoglobin levels | 73 |
| Circulating levels of plasminogen activator inhibitor-1 (PAI-1) | 303 |
| Circulating phospho- and sphingolipid concentrations | 49 |
| Circulating resistin levels | 246 |
| Circulating vitamin D levels in children with asthma | 184 |
| Cisplatin and carboplatin cytotoxicity, in blood cell lines | 1110 |
| Cisplatin cytotoxicity and gene expression, in blood cell lines | 601 |
| Cisplatin cytotoxicity, in blood cell lines | 1089 |
| Cisplatin-induced apoptosis and gene expression in blood cell lines | 1054 |
| Cleft lip (nonsyndromic cleft lip with or without cleft palate) | 693 |
| Cleft lip (nonsyndromic cleft lip) | 251 |
| Cleft lip, with or without cleft palate | 830 |
| Cleft palate (nonsyndromic cleft palate) | 1050 |
| Coagulation factor levels (FVII, FVIII, vWF), in plasma | 809 |
| Coagulation factors and fibrin factor levels and ischemic stroke | 439 |
| Coffee consumption | 1003 |
| Cognition (childhood intelligence) | 428 |
| Cognition (information processing speed) | 955 |
| Cognition (intelligence) | 1102 |
| Cognition (mathematical ability) | 771 |
| Cognition with anti-psychotic treatment | 946 |
| Cognition, early reading ability | 599 |
| Cognition, in schizophrenia | 1062 |
| Cognition, memory (episodic memory) | 587 |
| Cognition, memory (memory task performance) | 581 |
| Cognition, memory (short term memory) | 770 |
| Cognitive ability | 621 |
| Cognitive decline | 701 |
| Cognitive decline (nonpathological) | 382 |
| Cognitive decline (rate in Alzheimer’s disease) | 499 |
| Cognitive decline, age-related rate of | 1163 |
| Cognitive function, normal and in bipolar disorder and schizophrenia | 1185 |
| Cognitive impairment induced by topiramate | 1176 |
| Cognitive impairment without dementia | 322 |
| Cognitive performance | 737 |
| Colorectal adenomas | 554 |
| Colorectal and prostate cancer risk | 134 |
| Colorectal cancer | 172 |
| Colorectal cancer (drug response in metastatic colorectal cancer) | 979 |
| Colorectal cancer, efficacy of capecitabine, oxaliplatin and bevacizumab in metastatic colorectal cancer | 1207 |
| Colorectal cancer, severe oxaliplatin-induced chronic peripheral neuropathy in | 1153 |
| Common variable immunodeficiency | 1029 |
| Comorbid depressive syndrome and alcohol dependence | 1166 |
| Complement c3 and c4, serum | 315 |
| Compressive strength index (CSI) and appendicular lean mass (ALM) | 291 |
| Concentrations of cancer antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA) and _ fetoprotein (AFP) | 413 |
| Conduct Disorder | 854 |
| Confectionary intake | 449 |
| Congenital heart malformations (sporadic non-syndromic) | 564 |
| Congenital heart malformations (with septal, obstructive and cyanotic defects) | 565 |
| Copper, selenium and zinc levels | 569 |
| Corneal astigmatism | 1191 |
| Corneal curvature | 296 |
| Coronary artery and aortic artery calcification | 511 |
| Coronary artery calcification | 445 |
| Coronary artery disease | 38 |
| Coronary artery lesions in Kawasaki disease | 553 |
| Coronary artery stenosis | 214 |
| Coronary heart disease | 126 |
| Coronary heart disease (incident CHD) | 1106 |
| Coronary heart disease and related risk factors (LDL cholesterol, HDL cholesterol, hypertension, smoking, T2D) | 1000 |
| Coronary spasm | 622 |
| Cortical thickness, in brain | 1098 |
| Cortisol secretion, in saliva | 997 |
| Creatinine level, in serum | 808 |
| Creutzfeldt-Jakob disease | 1187 |
| Creutzfeldt-Jakob disease and other prion disease variants | 1204 |
| Creutzfeldt-Jakob disease variant | 670 |
| Crohn’s disease | 75 |
| Crohn’s disease (earlier required surgery) | 545 |
| Crohn’s disease and Celiac disease | 988 |
| Crohn’s disease and Psoriasis | 110 |
| Crohn’s disease and ulcerative colitis | 349 |
| Cystic fibrosis with meconium ileus | 98 |
| Cystic fibrosis, lung disease in | 690 |
| Cystic fibrosis, severity of | 1048 |
| Cytabarine toxicity in blood cell lines | 503 |
| Cytokine responses to Pam(3)CSK(4) (N-palmitoyl-S-dipalmitoylglyceryl Cys-Ser-(Lys)(4)) in blood | 363 |
| D-dimer levels, in plasma | 1030 |
| DNA methylation (allele-specific methylation), in blood cell lines | 792 |
| DNA methylation in blood | 571 |
| DNA methylation, in blood cell lines | 982 |
| Dabigatran plasma levels | 470 |
| Daunorubicin cytotoxicity and gene expression, in blood cell lines | 637 |
| Dehydroepiandrosterone sulphate (DHEAS) levels, in serum | 1038 |
| Dengue shock syndrome | 1143 |
| Dental caries | 397 |
| Dental caries in permanent dentition | 332 |
| Depressive affect | 889 |
| Diabetes in cystic fibrosis | 549 |
| Diabetic retinopathy | 902 |
| Differential cardiovascular event reduction by pravastatin therapy | 181 |
| Dilated cardiomyopathy | 920 |
| Disordered eating | 517 |
| Disordered gambling | 222 |
| Down’s Syndrome & Alzheimer’s disease | 529 |
| Drug response to interferon-beta therapy in multiple sclerosis (MS) | 1032 |
| Drug-induced liver injury (>200 drugs included) | 295 |
| Drug-induced liver injury with amoxicillin-clavulanate treatment | 1043 |
| Drug-induced liver injury with flucloxacillin treatment | 713 |
| Duodenal ulcer | 66 |
| Dupuytren’s disease | 919 |
| Dyslexia | 378 |
| Dyslexia (and mathematical ability) | 456 |
| ECG (Electrocardiogram measurements), PR interval | 353 |
| ECG (Electrocardiogram measurements), PR interval, QRS duration | 702 |
| ECG (Electrocardiogram measurements), PR interval, QRS interval, QTc interval | 777 |
| ECG (Electrocardiogram measurements), QRS duration | 469 |
| ECG (Electrocardiogram measurements), QRS interval | 938 |
| ECG (Electrocardiogram measurements), QT interval | 209 |
| ECG (Electrocardiogram measurements), QT interval change with iloperidone treatment in schizophrenia | 647 |
| ECG (Electrocardiogram measurements), QT interval prolongation with antipsychotic treatment | 910 |
| ECG (Electrocardiogram measurements), QT interval, PR interval, QRS duration, Heart rate variability | 498 |
| ECG (Electrocardiogram measurements), QT interval, PR interval, RR interval, Heart rate variability | 615 |
| ECG (Electrocardiogram measurements), RR interval | 767 |
| ECG (Electrocardiogram measurements), T-Peak to T-End interval | 45 |
| ECG (Electrocardiogram measurements), early repolarization pattern | 190 |
| ECG dimensions, brachial artery endothelial function, treadmill exercise responses | 611 |
| EEG measurements, in brain | 828 |
| Eating disorders | 270 |
| Economic and political preferences | 153 |
| Educational attainment | 570 |
| Effectiveness of iloperidone treatment in schizophrenia | 646 |
| Emphysema | 885 |
| End-stage renal disease | 754 |
| End-stage renal disease (ESRD), non-diabetic | 848 |
| Endometrial cancer | 3 |
| Endometriosis | 343 |
| Epilepsy | 1181 |
| Epilepsy (genetic generalized epilepsies) | 284 |
| Epilepsy (partial epilepsy) | 843 |
| Epirubicin-induced leukopenia in cancer patients | 1095 |
| Equol producers | 103 |
| Erectile dysfunction | 913 |
| Erectile dysfunction (ED) among prostate cancer patients treated with radiation therapy | 312 |
| Erectile dysfunction in Type 1 Diabetes | 203 |
| Eruption of permanent teeth | 1130 |
| Erythrocyte sedimentation rate | 1071 |
| Esophageal cancer (esophageal squamous cell carcinoma) | 41 |
| Esophageal cancer (esophageal squamous cell carcinoma) survival | 540 |
| Essential hypersomnia | 541 |
| Essential tremor | 220 |
| Etoposide cytotoxicity and gene expression in blood cell lines | 590 |
| Ewing sarcoma | 42 |
| Exercise participation | 735 |
| Eye color | 480 |
| FSH levels, anti-Mullerian hormone levels, in serum | 1182 |
| FVII levels | 1061 |
| FVIII levels, vWF levels | 1097 |
| Facial morphology | 317 |
| Facial photoaging | 387 |
| Factor XI Level and activated partial thromboplastin time (aPTT), in plasma | 201 |
| Familial hypercholesterolemia | 294 |
| Family chaos | 633 |
| Fasting glucose | 7 |
| Fasting glucose and insulin, and response to glucose in plasma | 256 |
| Fasting glucose, in plasma | 638 |
| Fasting glycemic traits and insulin resistance | 158 |
| Fasting insulin | 1121 |
| Fasting insulin processing and secretion in non-diabetics | 401 |
| Fasting insulin; insulin resistance | 225 |
| Fasting proinsulin levels in non-diabetics | 1114 |
| Fasting triglycerides, in plasma | 668 |
| Fatty acid levels, in plasma | 430 |
| Fatty liver and alanine aminotransferase levels (ALT) | 476 |
| Fenofibrate effects on circulating adiponectin | 360 |
| Ferritin and soluble transferrin receptor levels, in serum | 959 |
| Ferritin levels, in serum | 671 |
| Fetal growth and birth weight | 821 |
| Fetal hemoglobin levels | 280 |
| Fibrinogen (gamma fibrinogen) | 1086 |
| Fibrinogen levels | 922 |
| Fibrinogen levels, in plasma | 762 |
| Fibrinogen levels, in plasma, in women | 763 |
| Frontal cortex theta oscillations in alcoholism | 142 |
| Frontotemporal lobar degeneration with TDP-43 inclusions, in brain | 790 |
| Fuch’s corneal dystrophy | 893 |
| GABA concentration in the occipital cortex in children | 977 |
| Gains in maximal O(2) uptake (VO(2max)) after exposure to a standardized 20-wk exercise program | 4 |
| Gallbladder cancer | 37 |
| Gallstone disease | 595 |
| Gamma-glutamyl transferase (GGT) levels, in serum | 1150 |
| Gastric adenocarcinoma and esophageal squamous cell carcinoma | 888 |
| Gastric cancer (diffuse-type gastric cancer) | 644 |
| Gastric cancer (non-cardia gastric cancer) | 1158 |
| Gastric cancer, chemosensitivity to oxaliplatin, docetaxel and paclitaxel | 1202 |
| Gaucher disease | 67 |
| Gender | 51 |
| Gene expression and DNA methylation in 4 brain regions (pons, cerebellum, frontal cortex, temporal cortex) | 838 |
| Gene expression and DNA methylation in brain cerebellum | 6 |
| Gene expression in 3 blood cell types, in blood cell lines | 723 |
| Gene expression in CD4+ T cells in HIV-1 infected individuals | 803 |
| Gene expression in CD4+ lymphocytes | 896 |
| Gene expression in adipose and blood cells | 632 |
| Gene expression in basal cell carcinomas | 1149 |
| Gene expression in blood cell lines | 603 |
| Gene expression in blood cell lines (indel eQTLs) | 477 |
| Gene expression in blood cell lines (parent of origin effects) | 271 |
| Gene expression in blood cells | 193 |
| Gene expression in blood cells and fibroblasts | 550 |
| Gene expression in blood dendritic cells before and after exposure to Mycobacterium tuberculosis | 14 |
| Gene expression in brain (cerebellum and temporal cortex) | 191 |
| Gene expression in brain cortex | 619 |
| Gene expression in brain prefrontal cortex | 816 |
| Gene expression in breast tumors | 130 |
| Gene expression in cortex and peripheral blood mononuclear cells | 688 |
| Gene expression in cortex in Alzheimer’s disease and controls | 700 |
| Gene expression in cultured endothelial cells | 797 |
| Gene expression in endometrial cancer tumors | 976 |
| Gene expression in intestine | 474 |
| Gene expression in introns and nonsense-mediated decay in blood cell lines | 869 |
| Gene expression in leukemia cells and normal leukocytes | 643 |
| Gene expression in leukocytes | 676 |
| Gene expression in liver | 93 |
| Gene expression in monocytes | 840 |
| Gene expression in muscle | 990 |
| Gene expression in osteoblasts | 726 |
| Gene expression in osteoblasts and blood cell lines | 727 |
| Gene expression in skin cells | 953 |
| Gene expression in skin cells, adipose and blood cell lines, in women | 992 |
| Gene expression in sputum | 1134 |
| Gene expression in stomach, liver and adipose | 1047 |
| Gene expression in treated osteoblasts | 987 |
| Gene expression networks in adipose and blood | 62 |
| Gene expression of microRNA (miRNA) in abdominal and gluteal adipose | 1177 |
| Gene expression of microRNA (miRNA) in blood cell lines | 1067 |
| Gene expression of microRNA (miRNA) in fibroblasts | 958 |
| Gene expression of microRNAs (miRNA) and other small RNAs in adipose tissue | 161 |
| Gene expression of microRNAs (miRNA) in blood cell lines | 174 |
| Gene expression splicing and processing in glioblastoma cell lines | 99 |
| Glaucoma | 600 |
| Glaucoma (central corneal thickness in primary open-angle glaucoma) | 178 |
| Glaucoma (intraocular pressure and primary open-angle glaucoma) | 156 |
| Glaucoma (normal tension glaucoma) | 229 |
| Glaucoma (optic nerve degeneration in glaucoma) | 82 |
| Glaucoma, normal tension | 819 |
| Glaucoma, open angle | 1035 |
| Glaucoma, open-angle | 898 |
| Glaucoma, primary angle closure | 275 |
| Glaucoma, primary open-angle | 78 |
| Glaucoma, primary open-angle and age-related macular degeneration | 502 |
| Glaucoma-related traits | 1164 |
| Glioblastoma | 101 |
| Glioma | 258 |
| Glomerulosclerosis | 874 |
| Glucose homeostasis traits (fasting glucose, fasting insulin, HOMA-B, HOMA-IR) | 783 |
| Gout | 128 |
| Grave’s disease | 531 |
| HDL cholesterol | 318 |
| HDL cholesterol (high/low extremes) | 1206 |
| HDL cholesterol and triglyceride levels, in plasma | 626 |
| HDL particle features | 986 |
| HIV-1 (efavirenz pharmacokinetics) | 337 |
| HIV-1 acquisition | 52 |
| HIV-1 acquisition and viral load at set point | 1198 |
| HIV-1 control and progression | 928 |
| HIV-1 infection (development of cross-reacting neutralizing antibodies) | 434 |
| HIV-1 non-progression | 883 |
| HIV-1 non-progression (untreated, long term) | 15 |
| HIV-1 progression to AIDS and death | 1100 |
| HIV-1 replication | 1005 |
| HIV-1 resistance in highly exposed individuals with hemophilia A | 433 |
| HIV-1 susceptibility | 963 |
| HIV-1 viral load at set point | 772 |
| HIV-1, mother to child transmission | 839 |
| HIV-1/AIDS progression | 597 |
| HIV-associated neurocognitive disorders | 167 |
| Hair color | 143 |
| Hair color (red) | 1189 |
| Hair morphology | 750 |
| Hair, eye and skin pigmentation | 348 |
| Handedness | 535 |
| Health and aging, CVD and cancer age of onset | 1196 |
| Hearing function | 1028 |
| Hearing impairment, age related | 655 |
| Hearing impairment, age-related | 780 |
| Heart failure (incident risk) | 833 |
| Heart failure mortality among adults | 826 |
| Heart failure risk and mortality | 1001 |
| Heart failure with dilated cardiomyopathy | 1018 |
| Heart rate | 521 |
| Heart rate response to exercise training | 1197 |
| Heart rate, resting | 374 |
| Height | 466 |
| Height (in Pygmies) | 155 |
| Height (pubertal growth) | 462 |
| Height and body mass index | 824 |
| Height and body mass index (BMI) | 299 |
| Height, pubertal growth in | 825 |
| Helicobacter pylori serologic status | 543 |
| Hematological toxicities in cancer patients receiving gemcitabine therapy | 30 |
| Hemoglobin (HbA1c, glycated hemoglobin levels) | 27 |
| Hemoglobin A2 (HbA2) levels | 323 |
| Hemoglobin concentration | 849 |
| Hemoglobin levels | 744 |
| Hemoglobin levels, fetal hemoglobin levels in adults (HbF) by F cell levels | 602 |
| Hemoglobin levels, in serum | 745 |
| Hepatic adverse events with thrombin inhibitor ximelagatran | 588 |
| Hepatitis B virus (HBV) clearance | 210 |
| Hepatitis C infection | 776 |
| Hepatitis C virus-induced liver fibrosis | 245 |
| Hepatitis C-induced liver cirrhosis | 419 |
| Hepcidin, in serum | 1092 |
| Heroin addiction vulnerability | 842 |
| Hippocampal and intracranial volumes | 120 |
| Hippocampal volume | 124 |
| Hippocampal volume, total cerebral volume, white matter hyperintensities in Alzheimer disease patients | 213 |
| Hirschsprung’s disease | 684 |
| Hoarding behavior | 991 |
| Homocysteine levels, in plasma | 717 |
| Homocysteine levels, in plasma, in women | 764 |
| Human intelligence or general cognitive ability in ADHD families | 94 |
| Human papilloma virus seropositivity | 1117 |
| Huntington’s disease | 65 |
| Hypertension | 107 |
| Hypertension (essential hypertension) | 1200 |
| Hypertension and blood pressure traits | 64 |
| Hypertension with short sleep duration | 40 |
| Hypertension, salt-sensitive | 1045 |
| Hypertriglyceridemia | 867 |
| Hypertropic cardiomyopathy | 396 |
| Hypospadias | 947 |
| Hypothyroidism | 116 |
| Hypothyroidism and thyroid conditions | 1137 |
| IFN_ response to smallpox vaccine | 177 |
| IL-6 levels | 486 |
| IL-6, erythrocyte sedimentation rate, MCP-1, C-reactive protein (CRP) | 29 |
| Idiopathic premature ovarian failure | 1138 |
| Idiopathic pulmonary fibrosis | 661 |
| IgA deficiency (selective IgA deficiency) | 879 |
| IgA levels, in serum | 252 |
| IgE (total IgE) concentrations, plasma | 1172 |
| IgE levels, in serum | 359 |
| IgG index in multiple sclerosis | 388 |
| IgG level, in serum | 183 |
| IgM, in serum | 347 |
| Ileal carcinoids | 957 |
| Implantable cardioverter-defibrillator activation with life-threatening arrhythmias | 18 |
| Infant head circumference | 122 |
| Infantile hypertrophic pyloric stenosis | 34 |
| Inflammatory demyelinating disease | 746 |
| Insulin like growth factor levels | 973 |
| Insulin response | 706 |
| Insulin traits (Insulin sensitivity index (ISI), Insulin disposition index (IDI)) | 753 |
| Inter-adventitial common carotid artery diameter | 393 |
| Interferon-related cytopenia in hepatitis C | 1074 |
| Interleukin levels (IL10, IL1Ra, IL6), in plasma | 1203 |
| Interleukin levels (IL18 levels) | 789 |
| Intracranial aneurysm | 24 |
| Intracranial aneurysm, sporadic | 293 |
| Intracranial volume | 121 |
| Irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer | 179 |
| Iris color | 630 |
| Iris patterns | 1108 |
| Iron deficiency | 1026 |
| Iron levels, in serum | 749 |
| Job-related exhaustion | 533 |
| Joint damage in rheumatoid arthritis | 556 |
| Kawasaki disease | 91 |
| Keloid | 886 |
| Keratoconus | 1135 |
| Kidney function and endocrine traits (urinary albumin, creatinine, cystatin-C, thyroid stimulating hormone), in serum and in urine | 604 |
| Kidney stone disease | 718 |
| LDL cholesterol | 333 |
| LDL cholesterol in genotype-1 chronic hepatitis C | 118 |
| LDL cholesterol, coronary artery calcification | 929 |
| Lactate dehydrogenase, in serum | 923 |
| Lamotrigine- and phenytoin-induced hypersensitivity reactions | 61 |
| Late rectal bleeding following chemotherapy for prostate cancer | 568 |
| Lean body mass | 692 |
| Lean body mass; age at menarche | 212 |
| Left ventricular (LV) wall thickness | 971 |
| Left ventricular hypertrophy by electrocardiogram (ECG) | 1104 |
| Left ventricular mass | 710 |
| Lentiform nucleus volume | 266 |
| Leprosy | 760 |
| Leukemia (B-cell chronic lymphocytic leukemia) | 654 |
| Leukemia (acute lymphoblastic leukemia) (ALL) | 1173 |
| Leukemia (childhood acute lymphoblastic leukemia relapse) | 309 |
| Leukemia (childhood acute lymphoblastic leukemia) | 492 |
| Leukemia (childhood acute lymphoblastic leukemia) (ALL) | 875 |
| Leukemia (chronic lymphocytic leukemia) | 200 |
| Leukemia (chronic myeloid leukemia) | 1039 |
| Leukemia (pediatric acute lymphoblastic leukemia) | 730 |
| Leukemia, T-cell recognition in patients | 934 |
| Lipid level measurements | 170 |
| Lipid level measurements, blood pressure, albumin, CRP levels, fibrinogen, uric acid, white cell count, FII, FIII, vWF, glucose, insulin, waist circumference | 1154 |
| Lipid level measurements, in plasma | 743 |
| Lipid measurements and other quantitative traits (in serum: sodium, potassium, chloride, urea, creatinine, calcium, albumin, GGT, glucose, urate, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides; in urine: sodium, potassium, creatinine, albumin) | 625 |
| Lipoprotein A [Lp(a)] levels and coronary artery disease | 769 |
| Lipoprotein A [Lp(a)] levels in plasma | 1046 |
| Lipoprotein A [Lp(a)] levels in plasma, cardiovascular disease and mortality | 1119 |
| Lipoprotein A [Lp(a)] levels, in plasma | 675 |
| Lipoprotein-associated phospholipase A2 mass and activity; coronary heart disease | 1144 |
| Liver cancer (hepatocellular carcinoma) | 944 |
| Liver cancer (hepatocellular carcinoma) in patients with chronic hepatitis B virus infection | 233 |
| Liver cancer (hepatocellular carcinoma), progresstion to with chronic viral hepatitis | 1077 |
| Liver enzyme concentrations (alanine aminotransaminase, alkaline phosphatase, gamme-glutamyl transferase), in plasma | 666 |
| Long chain n-3 polyunsaturated fatty acid levels, in plasma | 1105 |
| Longevity | 22 |
| Longevity and age-related phenotypes (age at menopause, walking speed, biological age) | 607 |
| Longevity, exceptional | 857 |
| Low thyroid-stimulation hormone (TSH) levels and thyroid cancer | 19 |
| Lp-PLA(2) mass and activity at baseline and after 12 months of rosuvastatin therapy | 346 |
| Lp-PLA2 activity and mass | 832 |
| Lumbar disc degeneration | 304 |
| Lumiracoxib-related liver injury | 866 |
| Lung adenocarcinoma | 231 |
| Lung cancer | 264 |
| Lung cancer (DNA-repair capacity in lung cancer) | 344 |
| Lung cancer (interstitial lung disease in gefitinib-treated non-small-cell lung cancer) | 1093 |
| Lung cancer (lung adenocarcinoma stage) | 980 |
| Lung cancer (lung adenocarcinoma) | 653 |
| Lung cancer (non-small cell lung cancer) | 906 |
| Lung cancer (non-small cell lung cancer), hypertriglyceridemia with bexarotene treatment of | 1079 |
| Lung cancer (squamous cell carcinoma) | 424 |
| Lung cancer in never smokers | 812 |
| Lung cancer in never-smoking women | 355 |
| Lung cancer, non-small cell lung cancer prognosis | 357 |
| Lung cancer, prognosis in advanced non-small cell lung carcinoma with platinum-based chemotherapy | 255 |
| Lung cancer, small-cell | 949 |
| Lung cancer, smokers with versus smokers without | 579 |
| Lung cancer, survival in advanced non-small cell lung cancer with carboplatin and paclitaxel treatment | 939 |
| Lung cancer, survival in non-small cell lung carcinoma in never smokers | 560 |
| Lung cancer, survival in non-small cell lung carcinoma with platinum-based chemotherapy | 1024 |
| Lung cancer, survival in small cell lung cancer treated with irinitecan and cisplatin | 478 |
| Lung function | 408 |
| Lung function decline in adults with and without asthma | 80 |
| Lung function decline in mild to moderate chronic obstructive pulmonary disease | 301 |
| Lung function in textile workers with endotoxin exposure | 495 |
| Lung function phenotypes | 616 |
| Lung function with asthma | 504 |
| Lupus (neonatal lupus) | 872 |
| Lymphoma (Hodgkin’s lymphoma and Epstein-Barr virus status-defined subgroups) | 25 |
| Lymphoma (Hodgkin’s lymphoma) | 925 |
| Lymphoma (diffuse large B-cell lymphoma) | 1020 |
| Lymphoma (follicular lymphoma) | 314 |
| Lymphoma (non-Hodgkin lymphoma) | 722 |
| Lymphoma subtypes | 426 |
| Lypmhoma (nodular sclerosis Hodgkin lymphoma) | 1174 |
| Macronutrient intake | 432 |
| Magnesium levels, in serum | 882 |
| Major depression | 102 |
| Major depression (age of onset) | 272 |
| Major depression (suicidal thoughts and behavior) | 1083 |
| Major depression, gender differences | 1051 |
| Major depression, recurrent | 841 |
| Major depression, recurrent early onset | 786 |
| Major depression, side-effects of antidepressant treatment | 1160 |
| Major depressive disorder | 361 |
| Major mood disorder | 781 |
| Malaria | 567 |
| Malaria (severe malaria) | 263 |
| Malarial infection | 868 |
| Male fertility (family size, birth rate) | 171 |
| Malignant pleural mesothelioma | 534 |
| Mammographic density | 985 |
| Maternally-mediated genetic effects and parent-of-origin effects on risk of orofacial clefting | 77 |
| Matrix metalloproteinase (MMP-1) levels, in serum | 768 |
| Meningioma | 1096 |
| Meningococcal disease | 880 |
| Mercaptopurine toxicity in acute lymphoblastic leukemia | 248 |
| Metabolic response to hydrochlorothiazide | 447 |
| Metabolic side effects to antipsychotic drugs | 802 |
| Metabolic syndrome (HDL cholesterol, plasma glucose, T2D, waist to hip ratio, diastolic blood pressure) | 881 |
| Metabolic syndrome (HDL cholesterol, triglycerides, plasma glucose, waist circumference, systolic and diastolic blood pressure) | 72 |
| Metabolic syndrome (waist circumference, fasting glucose, HDL cholesterol, triglycerides, blood pressure) | 1009 |
| Metabolic traits (triglycerides, HDL cholesterol, LDL cholesterol, fasting plasma glucose, albumin, blood urea nitrogen, gamma-glutaryl transpeptidase, alanine aminotransferase, aspartate aminotransferase) | 1125 |
| Metabolite concentrations, gender-specific, in serum | 1111 |
| Metabolites and sphingolipids, circulating concentrations | 742 |
| Metabolites related insulin sensitivity in non-diabetics, in plasma | 437 |
| Metabolites, in plasma | 1129 |
| Metabolites, in serum | 26 |
| Metabolites, in serum in men | 667 |
| Metabolites, in serum in prostate cancer | 407 |
| Metabolites, in urine | 1044 |
| Methamphetamine dependence | 631 |
| Methamphetamine-induced psychosis and schizophrenia | 527 |
| Methotrexate clearance in acute lymphoblastic leukemia | 390 |
| Midregional-proadrenomedullin and C-terminal-pro-endothelin-1, in plasma | 438 |
| Migraine | 187 |
| Migraine without aura | 189 |
| Minor histocompatibility antigenicity in blood cell lines | 624 |
| Monoamine metabolite levels in cerebrospinal fluid | 417 |
| Monocyte chemoattractant protein-1 (MCP-1) in obese children | 311 |
| Monocyte colony-forming units (CFUs) | 1027 |
| Moyamoya disease | 927 |
| Multiple cancer types (lung cancer, noncardia gastric cancer, esophageal squamous-cell carcinoma) | 342 |
| Multiple myeloma | 1184 |
| Multiple sclerosis | 157 |
| Multiple sclerosis (brain lesion distribution in multiple sclerosis) | 450 |
| Multiple sclerosis (oligoclonal bands in multiple sclerosis) | 473 |
| Multiple sclerosis, glutamate concentrations in brains in | 891 |
| Multiple sclerosis, progressive | 96 |
| Multiple sclerosis, severity | 1056 |
| Multiple traits (Alzheimer’s disease, progressive supranuclear palsy, sudden infant death with dysgenesis of the testes syndrome) | 583 |
| Multiple traits (bipolar disorder, coronary artery disease, Crohn’s disease, rheumatoid arthritis, T1D, T2D, hypertension) | 31 |
| Multiple traits (coronary heart disease, T2D, LDL cholesterol, HDL cholesterol) | 1040 |
| Multiple traits (eye color, freckles, hair color, hair curl, asparagus anosmia, photic sneeze reflex, handedness, footedness, attached earlobes, dental work, myopia, taste preference, motion sickness, astigmatism) | 856 |
| Multiple traits (lipids, glucose, obesity, blood pressure) | 586 |
| Myasthenia gravis | 330 |
| Myeloperoxidase levels | 532 |
| Myeloproliferative neoplasm | 694 |
| Myocardial infarction | 573 |
| Myopia | 471 |
| Myopia (high myopia) | 325 |
| Myopia and refractive errors | 446 |
| Myopia, pathological | 740 |
| N-glycan levels, in plasma | 969 |
| N-glycosylation of IgG in plasma | 440 |
| NT-proBNP levels | 984 |
| Narcolepsy | 467 |
| Narcolepsy with cataplexy | 483 |
| Nasion Position | 44 |
| Nasopharyngeal carcinoma | 384 |
| Natural anticoagulant inhibitors and protein C anticoagulant pathway in venous thrombosis, in plasma | 89 |
| Nephrolithiasis | 70 |
| Nephropathy | 1012 |
| Nephropathy (Immunoglobulin A (IgA) nephropathy) | 574 |
| Nephropathy (diabetic nephropathy) | 207 |
| Nephropathy, idiopathic membranous | 998 |
| Nephrotic syndrome, acquired | 1017 |
| Neuroblastoma | 282 |
| Neuroblastoma (in low-risk cases) | 1015 |
| Neurodevelopmental phenotypes at four-year follow-up following cardiac surgery in infancy | 327 |
| Neurofibrillary tangles in non-demented elderly subjects, in brain | 834 |
| Neuropsychological treatments and metabolic and cardiovascular risk factors (HDL cholesterol, BMI) | 76 |
| Neuroticism | 389 |
| Neutropenia or leukopenia in response to chemotherapeutic agents | 542 |
| Nevirapine-induced rash | 1099 |
| Nevus count | 859 |
| Nicotine and alcohol dependence | 791 |
| Nicotine dependence | 59 |
| Nicotine dependence and smoking initiation | 1148 |
| Nicotine dependence, cigarettes per day | 131 |
| Nicotine dependence, relapse | 505 |
| Nicotine smoking | 683 |
| Nicotine, smoking behavior | 241 |
| Nicotine, smoking cessation | 645 |
| Nicotine, smoking quantity | 326 |
| Non-Albumin, albumin and total protein, serum | 144 |
| Non-obstructive azoospermia | 1201 |
| Nonalcoholic fatty liver disease | 206 |
| Nonobstructive Azoospermia | 136 |
| Nonsyndromic sagittal craniosynostosis | 367 |
| Nonsyndromic striae distensae | 536 |
| Obesity traits (body mass index (BMI), total fat mass), blood pressure | 1151 |
| Obesity traits in postmenopausal women | 379 |
| Obesity, childhood | 111 |
| Obesity, early onset | 514 |
| Obesity, early onset extreme | 623 |
| Obesity, early onset in children and adolescents | 829 |
| Obesity, extreme | 584 |
| Obesity, menopause | 1013 |
| Obesity-related traits | 678 |
| Obesity-related traits (body mass index (BMI), waist circumference, weight change, height, adiposity) | 610 |
| Obesity-related traits (body mass index (BMI), weight) | 669 |
| Obesity-related traits (body mass index (BMI), weight, hip circumference) | 598 |
| Obesity-related traits (body mass index (BMI), weight, hip circumference, waist circumference, brachial circumference, height) | 691 |
| Obesity-related traits, body mass index (BMI), blood pressure | 1208 |
| Obsessive-compulsive disorder | 259 |
| Ocular axial length and high myopia | 192 |
| Opiates addiction | 497 |
| Opioid sensitivity in healthy subjects | 375 |
| Optic disc area | 994 |
| Optic disc parameters | 851 |
| Optic nerve assessment | 823 |
| Osteoarthritis | 218 |
| Osteoarthritis (hand) | 715 |
| Osteoarthritis (hip) and joint-space width (cartilage thickness) | 152 |
| Osteoarthritis (knee and hip) | 964 |
| Osteoarthritis (knee) | 578 |
| Osteoarthritis (knee), in women | 642 |
| Osteonecrosis of the jaw | 650 |
| Osteoporosis | 732 |
| Osteoporotic fracture | 425 |
| Osteoporotic fractures (hip) | 1087 |
| Otitis media | 350 |
| Otosclerosis | 689 |
| Ovarian cancer | 230 |
| Ovarian cancer survival | 262 |
| Ovarian failure (premature ovarian failure) | 716 |
| Ovarian follicle number and menopause | 198 |
| Ovarian response to FSH stimulation in IVF | 996 |
| Oxidized LDL cholesterol levels | 395 |
| Paclitaxel sensitivity in NCI60 cancer cell lines | 995 |
| Paclitaxel-induced sensory peripheral neuropathy | 247 |
| Paget’s disease of bone | 831 |
| Pain relief with opioid treatment | 1052 |
| Pancreatic adenocarcinoma | 372 |
| Pancreatic cancer | 724 |
| Pancreatic cancer and survival | 180 |
| Pancreatic cancer, survival with gemcitabine treatment | 1190 |
| Panic disorder | 362 |
| Paraoxonase activity | 368 |
| Paraoxonase and arylesterase activities in serum | 298 |
| Parkinson’s disease | 87 |
| Parkinson’s disease (early onset) | 269 |
| Parkinson’s disease motor and cognitive outcomes | 175 |
| Parkinson’s disease, age at onset | 739 |
| Parkinsonism in schizophrenia patients, antipsychotic-induced | 728 |
| Pediatric eosinophilic esophagitis | 806 |
| Pelvic organ prolapse | 1178 |
| Pemphigus vulgaris | 85 |
| Percent mammographic density | 133 |
| Perception of the odorants androstenone and galaxolide | 53 |
| Pericardial fat | 162 |
| Periodontal pathogen colonization | 199 |
| Periodontitis | 751 |
| Periodontitis (chronic periodontitis) | 468 |
| Peripartum cardiomyopathy | 1058 |
| Peripheral artery disease (PAD) | 860 |
| Personality (temperament scales) | 878 |
| Personality disorders and adult ADHD | 297 |
| Personality traits | 544 |
| Personality traits and mood states | 168 |
| Personality traits and mood states (depressive affects) | 409 |
| Phosphorous concentrations, in serum | 852 |
| Physical activity | 1094 |
| Phytosterol levels, in serum | 847 |
| Pit-and-fissure- and smooth-surface carries | 472 |
| Placental abruption | 381 |
| Plasma uric acid level in obese and never-overweight individuals | 559 |
| Plasminogen activator inhibitor-1 (PAI1) levels, in plasma | 853 |
| Platelet CD36 surface expression | 1022 |
| Platelet aggregation | 844 |
| Platelet aggregation, pre-aspirin and post-aspirin | 846 |
| Platelet count (PLT) and platelet volume (MPV) | 79 |
| Platelet reactivity in patients with type 2 diabetes during acetylsalicylic acid (ASA) treatment | 329 |
| Platelet response, antiplatelets and cardiovascular outcomes | 443 |
| Platelet thrombus formation under high shear stress | 140 |
| Platelet volume (MPV) | 672 |
| Podoconiosis | 95 |
| Polycystic ovary syndrome | 257 |
| Polycystic ovary syndrome through obesity-related condition | 286 |
| Polysubstance addiction | 582 |
| Polyunsaturated fatty acid levels, in plasma | 677 |
| Post-operative nausea and vomiting | 1068 |
| Post-traumatic stress disorder (PTSD) | 254 |
| Pre-eclampsia | 84 |
| Premature ovarian failure | 39 |
| Preoperative chemoradiation therapy response in rectal cancer | 482 |
| Primary biliary cirrhosis | 278 |
| Primary nonsyndromic vesicoureteric reflex | 756 |
| Primary rhegmatogenous retinal detachment | 523 |
| Primary sclerosing cholangitis | 129 |
| Primary sclerosing cholangitis and ulcerative colitis | 236 |
| Primary tooth development during infancy | 804 |
| Primary tooth eruption | 561 |
| Progranulin levels, in plasma | 941 |
| Progressive supranuclear palsy | 585 |
| Prostate cancer | 55 |
| Prostate cancer and Type II Diabetes Mellitus | 593 |
| Prostate cancer gene 3 (PCA3) mRNA levels | 508 |
| Prostate cancer mortality | 921 |
| Prostate cancer, advanced | 1082 |
| Prostate cancer, aggressive | 674 |
| Prostate-specific antigen | 404 |
| Prostate-specific antigen (free-to-total, %fPSA), in serum | 429 |
| Prostate-specific antigen levels in men, in serum | 962 |
| Protein C levels and protein S levels, in plasma | 1205 |
| Protein expression in blood cell lines | 2 |
| Protein expression in blood plasma | 163 |
| Protein quantitative traits (42 protein levels in fasting serum and plasma: including C-reactive protein (CRP), IL6R, IL18, Lipoprotein A (LPA), GGT, IL1RN, TNFa, adiponectin, albumin, alkaline phosphatase, fibrinogen, ferritin, hemoglobin, insulin, leptin, SHBG, transferrin, thyroid stimulating hormone, MCP1) | 641 |
| Protein-C levels, in plasma | 890 |
| Pseudoexfoliation syndrome | 892 |
| Psoriasis | 354 |
| Psoriasis and psoriatic arthritis | 917 |
| Psoriasis risk prediction | 972 |
| Psoriatic arthritis | 1194 |
| Psychiatric disorders (Autism, ADHD, Bipolar disorder, Schizophrenia, Depression) | 464 |
| Pulmonary arterial hypertension | 484 |
| Pulmonary fibrosis (fibrotic idiopathic interstitial pneumonias) | 522 |
| Pulse pressure | 219 |
| Pulse pressure and mean arterial pressure | 1126 |
| Radiation-induced damage on blood cell lines | 911 |
| Recipient kidney allograft function | 459 |
| Recombination rate | 629 |
| Refractive errors | 475 |
| Renal cancer | 376 |
| Renal cell carcinoma | 956 |
| Renal cell carcinoma in stem cell transplantation | 1081 |
| Renal sinus fat accumulation | 1161 |
| Response to TNF_ inhibitors in patients with rheumatoid arthritis | 154 |
| Response to anti-TNF treatment in arthritis | 509 |
| Response to antidepressants | 738 |
| Response to antidepressants (citalopram-induced side effects) | 217 |
| Response to antidepressants (escitaloprim, nortriptyline) | 817 |
| Response to antidepressants (selective serotonin reuptake inhibitors (SSRIs)) | 268 |
| Response to antidepressants (sustained antidepressant response) | 572 |
| Response to antipsychotics | 748 |
| Response to antipsychotics (olanzapine, quetiapine, risperidone, ziprasidone, perhpenazine) | 733 |
| Response to antipsychotics in schizophrenia (treatment refractory) | 108 |
| Response to atorvastatin | 57 |
| Response to cholinesterase inhibitors in Alzheimer’s disease | 435 |
| Response to citalopram in major depressive disorder | 861 |
| Response to clopidogrel (anti-platelet), variation in | 731 |
| Response to fenofibrate | 261 |
| Response to fenofibrate treatment on inflammation biomarkers | 9 |
| Response to gemcitabine or arabinosylcytosin in blood cell lines | 752 |
| Response to glucocorticoid therapy in asthma | 1140 |
| Response to glucose and GLP-1-infusion on insulin secretion | 552 |
| Response to glucose and insulin | 782 |
| Response to glucose in plasma | 520 |
| Response to influenza vaccination | 113 |
| Response to interferon beta in multiple sclerosis | 627 |
| Response to lithium treatment in bipolar disorder | 708 |
| Response to metformin | 968 |
| Response to methylphenidate treatment | 954 |
| Response to pegylated interferon-alpha and ribavirin treatment in chronic hepatitis C | 729 |
| Response to platinum-based chemotherapy in small-cell lung cancer | 836 |
| Response to simvastatin | 341 |
| Response to statin treatment (atorvastatin), change in cholesterol levels | 766 |
| Response to statin treatment (simvastatin, pravastatin, atorvastatin), change in cholesterol levels | 813 |
| Response to statins | 43 |
| Response to statins (simvastatin, lovastatin) in NCI60 cancer cell lines | 1025 |
| Response to thiazide diuretic (hydrochlorothiazide) | 649 |
| Response to tocilizumab for the treatment of rheumatoid arthritis | 114 |
| Response to treatment (fludarabine, chlorambucil, combination) in chronic lymphocytic leukemia | 1057 |
| Response to treatment and survival on dialysis in T2D patients | 1041 |
| Response to treatment in pediatric acute lymphoblastic leukemia | 680 |
| Response to treatment with analgesics (midazolam, lidocaine) | 687 |
| Restenosis after percutaneous coronary intervention (PCI) | 741 |
| Resting heart rate | 865 |
| Restless leg syndrome | 596 |
| Retinal vascular caliber | 932 |
| Retinopathy (diabetic retinopathy) | 5 |
| Retinopathy (non-diabetic) | 444 |
| Rheumatoid arthritis | 92 |
| Rheumatoid arthritis, anti-TNF response in | 933 |
| Rheumatoid arthritis, cyclic citrullinated peptide (CCP) positive | 618 |
| SSRI/SNRI-induced sexual dysfunction in depression | 90 |
| Salmonella induced pyroptosis in B-lymphoblastoid cell lines | 244 |
| Sarcoidosis | 243 |
| Sasang constitution | 69 |
| Schizophrenia | 58 |
| Schizophrenia and bipolar disorder | 370 |
| Schizophrenia and bipolar disorder (joint pleiotropy) | 538 |
| Schizophrenia and brain fMRI during sensorimotor tasks | 88 |
| Schizophrenia symptoms (positive, negative/disorganized, mood) | 385 |
| Schizophrenia with formal thought disorder (disorganized speech) | 173 |
| Schizophrenia with negative symptoms | 441 |
| Schizophrenia, age at onset | 1066 |
| Schizophrenia, bipolar disorder and depression | 887 |
| Schizophrenia, treatment response to risperidone | 747 |
| Second to fourth digit length ratio | 399 |
| Selenium concentration, serum | 558 |
| Selenium resistance in NCI60 cancer cell lines | 895 |
| Self-employment | 526 |
| Self-rated health | 884 |
| Severity of response to H1N1 infection | 195 |
| Sex hormone-binding globulin (SHBG) concentrations | 239 |
| Sexual dysfunction (female) | 125 |
| Sick sinus syndrome | 1007 |
| Sickle cell anemia (haemolytic anemia) | 448 |
| Sickle cell anemia total bilirubin and cholelithiasis risk | 145 |
| Sickle cell anemia with elevated tricuspid regurgitation velocity | 188 |
| Sickle cell anemia, severity | 761 |
| Skin cancer (basal cell carcinoma) | 665 |
| Skin cancer (cutaneous basal cell carcinoma and squamous cell carcinoma) | 1072 |
| Skin cancer (cutaneous basal cell carcinoma) | 1133 |
| Skin cancer (cutaneous melanoma) | 1128 |
| Skin cancer (cutaneous nevi and melanoma risk) | 1023 |
| Skin cancer (malignant melanoma) | 575 |
| Skin cancer (melanoma) | 465 |
| Skin naphthyl-keratin adduct levels in workers exposed to naphthalene | 68 |
| Skin pigmentation | 620 |
| Skin pigmentation and skin cancer | 507 |
| Sleep and circadian phenotypes | 617 |
| Sleep apnea | 366 |
| Sleep duration | 1179 |
| Smallpox vaccine cytokine responses | 164 |
| Soluble CD14 | 369 |
| Soluble E-selectin levels, in plasma, in women | 788 |
| Soluble E-selectin levels, in serum | 736 |
| Soluble ICAM-1 levels, in women | 1037 |
| Soluble ICAM1 (sICAM) levels, in plasma, in women | 651 |
| Soluble P-selectin levels and soluble ICAM-1 levles | 796 |
| Soluble leptin receptor (sOB-R) levels, in plasma | 795 |
| Spine bone size | 383 |
| Spontaneous resolution of hepatitis C virus | 453 |
| Statin-Induced reductions in C-Reactive Protein | 11 |
| Statin-induced (cerivastatin) rhabdomyolysis | 1010 |
| Statin-induced myopathy | 652 |
| Stevens-Johnson syndrome | 916 |
| Stevens-Johnson syndrome and toxic epidermal necrolysis | 974 |
| Stressful life events | 391 |
| Stroke | 551 |
| Stroke in sickle cell anemia patients | 455 |
| Stroke, atherothrombotic | 773 |
| Stroke, ischemic | 320 |
| Stroke, ischemic stroke and large artery atherosclerosis | 281 |
| Stroke, large vessel ischemic | 33 |
| Stroke, pediatric | 302 |
| Subclinical atherosclerosis (coronary artery calcium, abdominal artery calcium, ankle-brachial index, carotid intimal media thickness) | 613 |
| Subcutaneous adipose tissue volume in HIV-infected men | 1118 |
| Subjective response to d-amphetamine in healthy subjects | 288 |
| Substance dependence | 1101 |
| Sudden cardiac arrest | 818 |
| Sudden cardiac death | 524 |
| Suicidal ideation with antidepressant (escitaloprim, nortriptyline) treatment | 908 |
| Suicidal ideation with antidepressant treatment | 1156 |
| Suicidal ideation with citalopram treatment | 734 |
| Suicide attempts in bipolar disorder patients | 926 |
| Suicide, with and without major depression | 1165 |
| Systemic lupus erythematosus | 28 |
| Systemic lupus erythematosus, in women | 628 |
| Systemic lupus erythematosus, rheumatoid arthritis | 328 |
| Systemic lupus erythematosus, serologic and cytokine (interferon gamma) profiles in serum in | 870 |
| Systemic sclerosis | 755 |
| Tamoxifen sensitivity and gene expression in blood cell lines | 488 |
| Tamsulosin hydrochloride pharmacokinetics in benign prostatic hyperplasia | 364 |
| Tanning ability | 698 |
| Tardive dyskinesia | 915 |
| Taste perception | 876 |
| Tau biomarkers (Ab1-42, t-tau, p-tau181p), in cerebrospinal fluid (CSF) | 950 |
| Tau protein levels, in cerebrospinal fluid (CSF) | 912 |
| Taxane response in lymphoblastoid cell lines and taxane-treated lung cancer survival | 308 |
| Telomere length | 306 |
| Telomere length (mean telomere length) | 501 |
| Temozolomide response in lymphoblastoid cell lines | 324 |
| Temperament | 240 |
| Temperament in bipolar disorder | 54 |
| Temporal lobe volumes | 805 |
| Testicular dysgenesis syndrome | 1188 |
| Testicular germ cell carcinoma | 712 |
| Testicular germ cell tumor | 547 |
| Testosterone concentration in men, in serum | 1142 |
| Tetralogy of Fallot | 412 |
| Theta band oscillations and alcohol dependence | 967 |
| Thiazolidinedione-induced edema | 863 |
| Thoracic aortic aneurysms and aortic dissections | 1123 |
| Thyroid cancer | 686 |
| Thyroid cancer, radiation-related | 815 |
| Thyroid function | 117 |
| Thyroid volume and goiter risk | 1042 |
| Thyrotoxic hypokalemic periodic paralysis | 71 |
| Thyrotoxic periodic paralysis | 250 |
| Thyrotropin and thyroid function, in serum | 894 |
| Total body bone mineral density | 226 |
| Tourette’s syndrome | 260 |
| Toxicity after 5-fluorouracil or FOLFOX administration for colorectal cancer | 35 |
| Trabecular and cortical volumetric BMD, bone microstructure | 461 |
| Transferrin glycosylation, in serum | 1059 |
| Transmission distortion | 60 |
| Treatment responses in severe sepsis | 36 |
| Tremors, antipsychotic-induced | 1139 |
| Trichophyton tonsurans susceptibility | 204 |
| Triglycerides levels, in serum, in men | 1195 |
| Troponin levels (highly sensitive cardiac troponin-T levels), in plasma | 394 |
| Tuberculosis | 17 |
| Tuberculosis (early age of onset) | 141 |
| Type I Diabetes | 316 |
| Type I Diabetes, autoantibody positivity in | 1107 |
| Type I Diabetes, serum ZnT8 autoantibody levels in | 132 |
| Type II Diabetes Mellitus | 16 |
| Type II Diabetes Mellitus (gestational diabetes) | 13 |
| Type II Diabetes Mellitus and gene expression in muscle and adipose tissue | 1055 |
| Type II Diabetes Mellitus and prostate cancer | 516 |
| Ulcerative colitis | 491 |
| Ulcerative colitis and Crohn’s disease | 1070 |
| Ulcerative colitis, refractory | 900 |
| Upper airway tract cancer | 1016 |
| Urate (in serum), gout | 400 |
| Uric acid levels, in serum | 10 |
| Urinary bladder cancer | 659 |
| Urinary symptoms following radiotherapy for prostate cancer | 436 |
| Uterine fibroids (benign tumors) | 1019 |
| Uterine leiomyomata | 319 |
| VLDL, LDL and HDL cholesterol particle size | 398 |
| Valvular calcification and aortic stenosis | 442 |
| Vascular dementia | 1180 |
| Vascular endothelial growth factor (VEGF) levels, in serum | 1085 |
| Venous thromboembolism | 182 |
| Venous thrombosis | 186 |
| Ventricular dysfunction after primary coronary artery bypass graft surgery | 1136 |
| Ventricular fibrillation in acute MI | 862 |
| Visceral adipose tissue-derived serine protease inhibitor (vaspin) | 267 |
| Visceral leishmaniasis | 410 |
| Visual cortical surface area | 46 |
| Vitamin A (retinol), circulating levels | 1116 |
| Vitamin B12 levels, in plasma, in women | 657 |
| Vitamin B12, in serum | 56 |
| Vitamin D (25(OH)D), circulating levels | 827 |
| Vitamin D concentrations | 850 |
| Vitamin E, circulating levels | 1078 |
| Vitiligo | 287 |
| Vitiligo, generalized | 148 |
| Waist circumference | 639 |
| Waist:hip ratio | 914 |
| Warfarin dose | 648 |
| Warfarin dose (acenocoumarol) | 720 |
| Warfarin responsiveness | 897 |
| Warfarin responsiveness (phenprocoumon) | 935 |
| Weight loss after Roux-en-Y gastric bypass surgery | 537 |
| Wheezing after influenza vaccination in children | 1011 |
| Wilms tumor | 138 |
| YKL-40 levels, in serum | 634 |
| _(2) -GPI levels, in plasma | 406 |
| _2-adrenoceptor-mediated vasoconstriction | 423 |
| t(11;14)(q13;q32) translocation in multiple myeloma | 485 |
| vWF levels, in plasma | 403 |
PhenoCat¶
The following 179 phenotype categories can be searched by alias or category:
| Category | ID | Alias |
|---|---|---|
| Addiction | 81 | addiction |
| Adipose-related | 84 | adipose |
| Adverse drug reaction (ADR) | 49 | adr |
| Age-related macular degeneration (ARMD) | 133 | armd |
| Aging | 44 | aging |
| Alcohol | 115 | alcohol |
| Allergy | 145 | allergy |
| Alzheimer’s disease | 99 | alzheimers |
| Amyotrophic lateral sclerosis (ALS) | 112 | als |
| Anemia | 127 | anemia |
| Aneurysm | 105 | aneurysm |
| Anthrax | 131 | anthrax |
| Anthropometric | 72 | anthropometric |
| Arterial | 106 | arterial |
| Arthritis | 61 | arthritis |
| Asthma | 1 | asthma |
| Atrial fibrillation | 123 | afib |
| Attention-deficit/hyperactivity disorder (ADHD) | 108 | adhd |
| Autism | 95 | autism |
| Basal cell cancer | 176 | basal_cell_cancer |
| Behavioral | 23 | behavioral |
| Bipolar disorder | 24 | bipolar |
| Bladder cancer | 165 | bladder_cancer |
| Bleeding disorder | 153 | bleeding_disorder |
| Blood | 177 | blood |
| Blood cancer | 52 | blood_cancer |
| Blood pressure | 59 | bp |
| Blood-related | 8 | blood |
| Body mass index | 75 | bmi |
| Bone cancer | 160 | bone_cancer |
| Bone-related | 47 | bone |
| Brain cancer | 111 | brain_cancer |
| Breast cancer | 25 | breast_cancer |
| C-reactive protein (CRP) | 29 | crp |
| CVD | 178 | cvd |
| CVD risk factor (CVD RF) | 27 | cvd_risk |
| Calcium | 155 | calcium |
| Cancer | 10 | cancer |
| Cancer-related | 86 | cancer_related |
| Cardiomyopathy | 152 | cardiomyopathy |
| Cardiovascular disease (CVD) | 38 | cvd |
| Celiac disease | 162 | celiac |
| Cell line | 9 | cell_line |
| Cervical cancer | 158 | cervical_cancer |
| Chronic kidney disease | 113 | chronic_kidney_disease |
| Chronic lung disease | 3 | chronic_lung_disease |
| Chronic obstructive pulmonary disease (COPD) | 140 | copd |
| Cognition | 107 | cognition |
| Colorectal cancer | 66 | colorectal_cancer |
| Congenital | 96 | congenital |
| Coronary heart disease (CHD) | 120 | chd |
| Crohn’s disease | 63 | crohns |
| Cystic fibrosis | 110 | cf |
| Cytotoxicity | 169 | cytotoxicity |
| Dental | 48 | dental |
| Depression | 104 | depression |
| Developmental | 43 | developmental |
| Diet-related | 100 | diet |
| Drug response | 26 | drug_response |
| Drug treatment | 179 | drug_treatment |
| Emphysema | 168 | emphysema |
| Endometrial cancer | 11 | endometrial_cancer |
| Environment | 87 | environment |
| Epigenetics | 22 | epigenetics |
| Epilepsy | 83 | epilepsy |
| Esophageal cancer | 70 | espohageal_cancer |
| Eye-related | 17 | eye |
| Female | 14 | female |
| Gallbladder cancer | 67 | gallbladder_cancer |
| Gallstones | 125 | gallstones |
| Gastric cancer | 147 | gastric_cancer |
| Gastrointestinal | 65 | gi |
| Gender | 13 | gender |
| Gene expression (RNA) | 19 | rna_expression |
| Gene expression (protein) | 6 | gene_protein_expression |
| General health | 167 | health |
| Glaucoma | 97 | glaucoma |
| Graft-versus-host | 164 | graft_v_host |
| Grave’s disease | 94 | graves |
| HIV/AIDS | 35 | hiv |
| Hair | 124 | hair |
| Hearing | 148 | hearing |
| Heart | 37 | heart |
| Heart failure | 163 | heart_failure |
| Heart rate | 149 | heart_rate |
| Height | 128 | height |
| Hemophilia | 154 | hemophilia |
| Hepatic | 89 | hepatic |
| Hepatitis | 118 | hepatitis |
| Hormonal | 42 | hormonal |
| Huntington’s disease | 88 | huntingtons |
| Imaging | 73 | imaging |
| Immune-related | 50 | immune |
| Infection | 33 | infection |
| Inflammation | 4 | inflammation |
| Influenza | 117 | flu |
| Kidney cancer | 150 | kidney_cancer |
| Leukemia | 53 | leukemia |
| Lipids | 28 | lipids |
| Liver cancer | 136 | liver_cancer |
| Lung cancer | 58 | lung_cancer |
| Lymphoma | 54 | lyphoma |
| Male | 78 | male |
| Manic depression | 175 | manic |
| Melanoma | 157 | melanoma |
| Menarche | 134 | menarche |
| Menopause | 45 | menopause |
| Methylation | 21 | methylation |
| Mood disorder | 166 | mood_disorder |
| Mortality | 31 | mortality |
| Movement-related | 130 | movement |
| Multiple sclerosis (MS) | 109 | ms |
| Muscle-related | 93 | muscle |
| Musculoskeletal | 114 | msk |
| Myasthenia gravis | 146 | myasthenia |
| Myocardial infarction (MI) | 39 | mi |
| Narcotics | 139 | narc |
| Nasal | 71 | nasal |
| Nasal cancer | 151 | nasal_cancer |
| Neuro | 20 | neuro |
| Obsessive-compulsive disorder (OCD) | 142 | ocd |
| Oral cancer | 119 | oral_cancer |
| Oral-related | 46 | oral |
| Ovarian cancer | 135 | ovarian_cancer |
| Pain | 143 | pain |
| Pancreas | 57 | pancreas |
| Pancreatic cancer | 56 | pancreatic_cancer |
| Parkinson’s disease | 101 | parkinsons |
| Physical activity | 16 | activity |
| Plasma | 76 | plasma |
| Platelet | 98 | platlet |
| Pregnancy-related | 32 | pregnancy |
| Prostate cancer | 79 | prostate_cancer |
| Protein expression | 7 | protein_expression |
| Pulmonary | 2 | pulmonary |
| Quantitative trait(s) | 5 | quantitative |
| Radiation | 144 | radiation |
| Rectal cancer | 159 | rectal_cancer |
| Renal | 91 | renal |
| Renal cancer | 122 | renal_cancer |
| Reproductive | 12 | reproductive |
| Rheumatoid arthritis | 62 | rheumatoid |
| Salmonella | 141 | salmonella |
| Schizophrenia | 80 | schizophrenia |
| Serum | 30 | serum |
| Sickle cell anemia | 126 | sickle_cell |
| Skin cancer | 156 | skin_cancer |
| Skin-related | 69 | skin |
| Sleep | 68 | sleep |
| Smallpox | 121 | smallpox |
| Smoking | 82 | smoking |
| Social | 90 | social |
| Stone | 92 | stone |
| Stroke | 51 | stroke |
| Subclinical CVD | 77 | subclin_cvd |
| Surgery | 36 | surgery |
| Systemic lupus erythematosus (SLE) | 55 | sle |
| T2D-related | 170 | t2d_related |
| Testicular cancer | 161 | testicular |
| Thrombosis | 103 | thrombosis |
| Thyroid | 41 | thyroid |
| Thyroid cancer | 40 | thyroid_cancer |
| Treatment response | 15 | treatment_response |
| Treatment-related | 171 | treatment |
| Tuberculosis | 34 | tb |
| Type 1 diabetes (T1D) | 60 | t1d |
| Type 2 diabetes (T2D) | 18 | t2d |
| Ulcerative colitis | 138 | ulc_colitis |
| Upper airway tract cancer | 172 | upper_airway_cancer |
| Urinary | 85 | urinary |
| Uterine cancer | 173 | uterine_cancer |
| Uterine fibroids | 174 | uterine_fibroids |
| Vaccine | 116 | vaccine |
| Valve | 132 | valve |
| Vasculitis | 137 | vasculitis |
| Venous | 102 | venous |
| Weight | 74 | weight |
| Wound | 64 | wound |
| miRNA | 129 | mirna |
Population¶
The following populations are available in the Population table:
| Population | ID |
|---|---|
| Hispanic | 1 |
| European | 2 |
| Mixed | 3 |
| African | 4 |
| Asian | 5 |
| Unspecified | 6 |
| Indian/South Asian | 7 |
| Micronesian | 8 |
| Arab/ME | 9 |
| Native | 10 |
| Filipino | 11 |
| Indonesian | 12 |
PopFlags¶
The following populations are available in the Population table:
| FLAG | Label |
|---|---|
| 1 | eur |
| 2 | afr |
| 4 | east_asian |
| 8 | south_asian |
| 16 | his |
| 32 | native |
| 64 | micro |
| 128 | arab |
| 256 | mix |
| 512 | uns |
| 1024 | filipino |
| 2048 | indonesian |